11 HURLEY ST., CAMBRIDGE, MA
Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
Announces Second Quarter 2025 Results and Business Updates
Editas Medicine's In Vivo HBG1/2 Editing for Sickle Cell and Beta Thalassemia
News, Articles of Incorporation, Material Contracts
Reports New In Vivo Data Highlighting the Potential of Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
Earnings Release
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
Confidential Treatment Order
SEC Staff Correspondence
Prospectus filed pursuant to Rule 424(b)(7)